Evidence map›Paper›PMID 36633609›Full record

ArticleArchives of toxicology2023

Pretreatment of rhesus monkeys with transdermal patches containing physostigmine and procyclidine: implications of the delivery system for the potential application against VX nerve agent intoxication in humans.

Ji-Hye Nam, Min-Soo Kim, Young-Jo Song, Chang-Hwan Kim, Wang Soo Kim, Chi Ho Yu, Hae Eun Joe, Gyeung Haeng Hur, Myeung-Ryun Seo, Yeongmun Kim and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 3 countries.

Ji-Hye Nam *Laboratory of Molecular Pathology and Cancer Genomics, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea.
Min-Soo Kim *College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.
Young-Jo Song *Agency for Defense Development, Yuseong, Daejeon, 34186, Republic of Korea.
Chang-Hwan KimAgency for Defense Development, Yuseong, Daejeon, 34186, Republic of Korea.
Wang Soo KimAgency for Defense Development, Yuseong, Daejeon, 34186, Republic of Korea.
Chi Ho YuAgency for Defense Development, Yuseong, Daejeon, 34186, Republic of Korea.
Hae Eun JoeLaboratory of Molecular Pathology and Cancer Genomics, College of Pharmacy and Research Institute of Pharmaceutical Science, Seoul National University, Seoul, 08826, Republic of Korea.
Gyeung Haeng HurAgency for Defense Development, Yuseong, Daejeon, 34186, Republic of Korea.
Myeung-Ryun SeoLaboratory of Molecular Pathology and Cancer Genomics, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea.
Yeongmun KimLaboratory of Molecular Pathology and Cancer Genomics, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea.
Kyung Eui ParkAbion Inc, Seoul, 08394, Republic of Korea.
Jun Young ChoiAbion Inc, Seoul, 08394, Republic of Korea.
Suk-Jae Chung *College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea. sukjae@snu.ac.kr.
Young Kee Shin *Laboratory of Molecular Pathology and Cancer Genomics, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea. ykeeshin@snu.ac.kr.ORCID 0000-0003-0896-718X
Seoul National University · KRAgency for Defense Development · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Physostigmine (Phs) is a reversible inhibitor of acetylcholinesterase (AChE) that penetrates the blood-brain barrier (BBB) and could be used to protect the central nervous system (CNS) against the effects of nerve agents. For prophylactic effectiveness, long, steady, and adequate inhibition of AChE activity by Phs is needed to broadly protect against the CNS effects of nerve agents. Here, we evaluated the efficacy of transdermal patches containing Phs and procyclidine (PC) as prophylactic agents. Patches (25 cm

Indexed as

Nerve AgentsSomanAcetylcholinesteraseAnimalsCholinesterase InhibitorsHumansMacaca mulattaOrganothiophosphorus CompoundsPhysostigmineProcyclidineAcetylcholinesteraseCholinesterase InhibitorsNerve AgentsOrganothiophosphorus CompoundsPhysostigmineProcyclidineSomanVX-agentAcetylcholinesteraseHumanPBPK/PD modelPhysostigmineProcyclidineRhesus monkeyTransdermal patchVX

Identifiers

PMID36633609
OpenAlexW4315702484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.